Altimmune, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ALT Nasdaq 2836 altimmune.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Altimmune, Inc.

Altimmune (ALT) Is Up 13.0% After FDA Breakthrough Tag For Pemvidutide In MASH - Has The Bull Case Changed? - Jan 8th, 2026 8:15 pm
ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH - Jan 6th, 2026 9:53 am
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH - Jan 5th, 2026 5:30 am
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround - Dec 29th, 2025 8:15 am
Jerome Durso Buys Handful Of Shares In Altimmune - Dec 28th, 2025 5:33 am
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial - Dec 19th, 2025 4:30 am
Does Altimmune (ALT) Have the Potential to Rally 229.28% as Wall Street Analysts Expect? - Dec 11th, 2025 7:55 am
Altimmune Announces CEO Transition and Succession Plan - Dec 1st, 2025 5:30 am
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference - Nov 26th, 2025 5:30 am
Wall Street Analysts Predict a 250.59% Upside in Altimmune (ALT): Here's What You Should Know - Nov 25th, 2025 7:55 am
Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025 - Nov 11th, 2025 6:51 am
Altimmune price target lowered to $14 from $15 at Citizens JMP - Nov 8th, 2025 4:05 am
Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025 - Nov 7th, 2025 6:05 am
Altimmune Announces Third Quarter 2025 Financial Results and Business Updates - Nov 6th, 2025 5:00 am
Altimmune to Participate in Two Upcoming Investor Conferences - Nov 5th, 2025 5:30 am
Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder - Nov 3rd, 2025 5:30 am
3 Explosive Stocks With High Short Interest - Oct 31st, 2025 9:18 am
Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025 - Oct 30th, 2025 5:30 am
Pleasing Signs As A Number Of Insiders Buy Altimmune Stock - Oct 8th, 2025 4:27 am
Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide - Sep 29th, 2025 5:30 am